Dermata Therapeutics, Inc.
DRMA
$6.45
$0.2183.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.06M | 1.01M | 824.30K | 874.60K | 1.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.34M | 3.20M | 3.23M | 2.88M | 3.20M |
| Operating Income | -2.34M | -3.20M | -3.23M | -2.88M | -3.20M |
| Income Before Tax | -2.30M | -3.15M | -3.17M | -2.83M | -3.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.30M | -3.15M | -3.17M | -2.83M | -3.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.30M | -3.15M | -3.17M | -2.83M | -3.13M |
| EBIT | -2.34M | -3.20M | -3.23M | -2.88M | -3.20M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4.47 | -9.17 | -20.41 | -41.82 | -70.59 |
| Normalized Basic EPS | -2.79 | -5.73 | -12.76 | -26.13 | -44.12 |
| EPS Diluted | -4.47 | -9.17 | -20.41 | -41.82 | -70.59 |
| Normalized Diluted EPS | -2.79 | -5.73 | -12.76 | -26.13 | -44.12 |
| Average Basic Shares Outstanding | 515.50K | 343.70K | 155.50K | 67.70K | 44.40K |
| Average Diluted Shares Outstanding | 515.50K | 343.70K | 155.50K | 67.70K | 44.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |